Immunoscintigraphy in patients with colorectal, ovarian, and prostate cancer. Results with site‐specific immunoconjugates

Abstract

Application of monoclonal antibody (MoAb) technology to cancer management is discussed by reviewing the development and clinical evaluation of two MoAb‐based immunoscintigraphic agents (111In‐satumomab pendetide [OncoScint CR/OV‐In] and 111In‐CYT‐356; Cytogen Corporation, Princeton, NJ). Both agents were prepared using a site‐specific MoAb modification method that preserves the immunoreactivity of the radiolabeled immunoconjugate. 111In‐satumomab pendetide is an 111 In‐labeled conjugate of the murine MoAb B72.3, which is directed to TAG‐72, an antigen expressed by the majority of adenocarcinomas. By providing information that complements the results of standard radiographic diagnostic modalities, this imaging agent can aid in the treatment of patients with colorectal or ovarian cancer. Immunoscintigraphy with 111In‐satumomab pendetide has been shown to assist in medical‐surgical management by detecting occult extrahepatic lesions, clarifying equivocal results of other diagnostic imaging tests, and evaluating the extent and resectability of known tumor lesions. 111In‐CYT‐356 is an 111In‐labeled conjugate of the murine MoAb 7E11‐C5.3, which is reactive with prostatic carcinoma, benign prostatic hypertrophy, and, to a lesser extent, normal prostatic tissue. Results of preliminary clinical investigations suggest that 111In‐CYT‐356 immunoscintigraphy can be useful for the presurgical staging of prostatic carcinoma and for the detection of occult distant disease in patients with negative or equivocal results on standard imaging tests. Results with these site‐specifically radiolabeled immunconjugates demonstrate the clinical utility of MoAb‐based imaging agents in the treatment of patients with solid tumors.

Clinical utility of indium 111‐capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy

“…Prior investigations have demonstrated that 111 In-capromab pendetide immunoscintigraphy is safe, with mild adverse effects and minimally elevated human antimouse antibody levels on rare occasion. 18,19 PSMA is a 100-kD transmembrane glycoprotein produced by both benign and malignant prostate epithelial cells. PSMA is expressed more abundantly in malignant prostate tissue compared with normal or hypertrophic prostate tissue and in poorly differentiated tumors compared with well-differentiated tumors.…”

Preoperative Clinical Radioimmunodetection of Pancreatic Cancer by 111In‐labeled Chimeric Monoclonal Antibody Nd2

“…The RAID of malignant disease with MoAb can be valuable in terms of detection (location, staging, and recurrence), differential diagnosis, and selection of patients for therapy. Although RAIDs have been successfully applied to several kinds of malignant tumors in organs such as colon, [2][3][4] lung, 12) and others, 13) there have been few studies on pancreatic cancer. 14,15) 111 In usually accumulates nonspecifically in the reticuloendothelial system, such as liver, spleen and bone marrow.…”

Prostate cancer: the contribution of nuclear medicine

“…The complete conjugate is thus 111 In‐anti‐PSMA‐DTPA‐glycosyl‐tyrosyl‐lysine. This In‐labelled monoclonal antibody has been evaluated clinically in patients with prostate cancer [36–51, Fenely MR, unpublished data]. PSMA is labelled with 99m Tc using a reduction technique [52,53] and has been called Prostatec ® ; it has also been evaluated clinically [54–57].…”